Electrical Geodesics, Inc Trading Update (4382O)
February 09 2016 - 1:00AM
UK Regulatory
TIDMEGI
RNS Number : 4382O
Electrical Geodesics, Inc
09 February 2016
Electrical Geodesics, Inc.
Trading Update
EUGENE, OREGON, US, 09 February 2016 - Electrical Geodesics,
Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical
technology company, today provides a trading update for the year
ended 31 December 2015. EGI will announce its audited results for
the year ended 31 December 2015 on 19 April 2016. The Company has
taken the decision to report its results under US GAAP
henceforward. The results reported below are expected to be
substantially the same under US GAAP and IFRS.
On a preliminary, unaudited basis, the Company expects to report
revenues for the year ended 31 December 2015 of $13.8m, an increase
of 4% over the $13.2m reported for 2014. In addition, the Company
expects to recognise grant income of some $1.5m for 2015 (2014:
$0.6m). Following a somewhat disappointing first half performance
when revenues of $5.2m were recorded (10% down on the prior year),
revenues in the second half of 2015 were strong at $8.6m,
representing a 15% increase over the same period in 2014. The
Company closed the year with approximately $1.0m of unfilled
orders, around half of which should be fulfilled in the first
quarter, with the balance being pre-orders for GTEN (Geodesic
Transcranial Electrical Neuromodulation) systems likely to be
filled in the second half of 2016. The balance ($1.3m) of the
ElMindA supply contract will also be filled during 2016.
The Company's cash reserves as at 31 December 2015 were
approximately $1.2m ($1.4m at 30 June 2015) and invoice-factoring
facilities are in place to help manage cash flows. The Company
expects the recent pattern of revenues being materially second half
weighted to be a feature of the current financial year. The
Directors are carefully managing the Company's cash flows whilst
also reviewing options to increase the working capital available to
the Group so that growth opportunities can be exploited.
On an operating basis, EGI is pleased to report the
following:
-- Product development is on track for a Q3 2016 research
release of the Company's flagship source imaging program GeoSource
3.0 which will feature individual head modeling capabilities and
expanded atlas modeling. This product is a companion product to the
GTEN product which is also expected to be released to the research
market in Q3 2016.
-- The clinical trial for dense array EEG localisation and GTEN
(Geodesic Transcranial Electrical Neuromodulation) treatment of
focal epilepsy is progressing well. At the US site, Harborview
Hospital University of Washington (Seattle), 15 patients have been
evaluated in the diagnostic phase and the intervention phase is
planned to start in March 2016. The diagnostic phase is now
underway at the China site, Huashan Hospital, Fudun University
(Shanghai).
-- The release in Q4 2015 of a range of Geodesic Sensor Nets
targeted at the particular needs of the underserved neonatal
intensive care market.
-- The submission of an Investigational Device Exemption (IDE)
for the study of dense array EEG localisation and rTMS (repetitive
Transcranial Magnetic Stimulation) treatment of focal epilepsy. The
study will take place at Stanford University Hospital.
-- Gary Weber has joined EGI as its CFO on an interim basis.
Gary has extensive experience with American publicly traded
companies and recently served as CFO for the fine chemicals
company, Synthetech Inc. Christine Soden, the Company's former CFO
remains on the Board as a non-executive Director.
Don Tucker, CEO of EGI, commented: "It is a pleasure to report
solid growth for 2015, despite a difficult first half which saw
unusually weak trading conditions in a number of our key markets,
driven by our advancing product line and expanded indications. Our
results reflect expansion in both clinical and research sectors of
the US market as well as some stability in our key international
markets. With a strong pipeline of new products and our key Phase I
trials underway we feel positioned for continuing growth in 2016.
We firmly believe that our strength in electrical source imaging
and our new GTEN technology will combine to provide a new level of
precision in electrical neuromodulation that will attract both
research and clinical customers. The evidence continues to be
strong that non-invasive neuromodulation through both TES and TMS
will be significant in the future treatment of many neurological
disorders."
For more information contact:
EGI
Ann Bunnenberg +1 541 687 7962
Peel Hunt LLP (NOMAD and
Broker)
+44 (0) 20 7418
James Steel, Tom Burt 8900
Notes to Editors
Electrical Geodesics, Inc. in Summary
Founded in 1992, EGI designs, develops and commercialises a
range of non-invasive neurodiagnostic and neuromodulation products
used to monitor, interpret and modulate brain activity, based on
its proprietary dense array electroencephalography ("dEEG")
platform technology. The Company's technology uses up to 256
sensors, providing much higher resolution brain activity data
compared to conventional 8 or 16 channel EEG and is used in
medical, clinical and research settings in a diverse range of
applications including important areas such as the diagnosis and
monitoring of epilepsy, neurosurgical planning, sleep assessment,
and many others.
EGI's dEEG systems, available in the GES 300 and now the GES 400
lines, capitalise on the Company's unique Hydrocel Geodesic Sensor
Net which allows faster, easier, and more convenient placement of
many EEG sensors in an even distribution over the entire scalp,
providing more accurate and precise diagnosis and measurement.
EGI's technology is now widely used in neuroscience research
laboratories and is becoming more commonly used in clinics, care
centers, and hospitals around the world. Data is measured and
visualised using EGI's proprietary amplifier technology and
software, providing a complete, advanced, high-resolution EEG
platform. The Company's products are compatible with multiple
diagnostic and imaging technologies, including magnetic resonance
(MR) imaging, functional MRI (fMRI), and magneto-encephalography
(MEG).
See our website www.egi.com
Glossary
EEG Electroencephalography
dEEG Dense-array EEG
GTEN Geodesic transcranial electrical
neuromodulation
MRI Magnetic resonance imaging
fMRI Functional MRI
PET Positron emission tomography
MEG Magneto encephalography
NIRS Near-infra-red spectroscopy
TES Trans-cranial electrical
stimulation
TMS Trans-cranial magnetic stimulation
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFVDFLITIIR
(END) Dow Jones Newswires
February 09, 2016 02:00 ET (07:00 GMT)
Elec Geo(DI) (LSE:EGI)
Historical Stock Chart
From May 2024 to Jun 2024
Elec Geo(DI) (LSE:EGI)
Historical Stock Chart
From Jun 2023 to Jun 2024